Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan

Ayako Nishino, Shin ya Kawashiri, Tomohiro Koga, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Yukitaka Ueki, Tamami Yoshitama, Nobutaka Eiraku, Naoki Matsuoka, Akitomo Okada, Keita Fujikawa, Hiroaki Hamada, Tomomi Tsuru, Shuji Nagano, Yojiro Arinobu, Toshihiko Hidaka, Atsushi Kawakami

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To explore the variables associated with initial favorable power Doppler (PD) ultrasound (US) response induced by biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA). Methods: We have been prospectively investigating the course of active RA patients using US after the introduction of b/tsDMARDs in the Kyushu region of Japan since June 2013. A total of 150 patients have completed the first 6 months of observation at present and have been evaluated. US was assessed in 22 joints of bilateral hands using gray-scale and PD images on a scale from 0–3. The sum of these scores was used as the indicator of US disease activity. We defined PD remission as attaining a total PD score of 0 at 6 months and investigated the associated variables by multivariate logistic regression analysis. Results: The total PD and gray-scale scores and the clinical composite measures significantly improved at 6 months, whereas these reductions were less in bDMARD switchers as compared with bDMARD-naive patients. Multivariate logistic regression analysis showed that short disease duration, the absence of any previous use of bDMARDs, and low total PD scores at baseline were independent predictors of PD remission at 6 months. Conclusion: This present prospective US cohort has for the first time shown the variables that are associated with initial PD response to b/tsDMARDs.

Original languageEnglish
Pages (from-to)1719-1726
Number of pages8
JournalArthritis Care and Research
Volume70
Issue number12
DOIs
Publication statusPublished - Dec 1 2018
Externally publishedYes

Fingerprint

Antirheumatic Agents
Rheumatoid Arthritis
Japan
Drug Therapy
Logistic Models
Regression Analysis
Hand Joints
Doppler Ultrasonography
Observation

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan. / Nishino, Ayako; Kawashiri, Shin ya; Koga, Tomohiro; Iwamoto, Naoki; Ichinose, Kunihiro; Tamai, Mami; Nakamura, Hideki; Origuchi, Tomoki; Ueki, Yukitaka; Yoshitama, Tamami; Eiraku, Nobutaka; Matsuoka, Naoki; Okada, Akitomo; Fujikawa, Keita; Hamada, Hiroaki; Tsuru, Tomomi; Nagano, Shuji; Arinobu, Yojiro; Hidaka, Toshihiko; Kawakami, Atsushi.

In: Arthritis Care and Research, Vol. 70, No. 12, 01.12.2018, p. 1719-1726.

Research output: Contribution to journalArticle

Nishino, A, Kawashiri, SY, Koga, T, Iwamoto, N, Ichinose, K, Tamai, M, Nakamura, H, Origuchi, T, Ueki, Y, Yoshitama, T, Eiraku, N, Matsuoka, N, Okada, A, Fujikawa, K, Hamada, H, Tsuru, T, Nagano, S, Arinobu, Y, Hidaka, T & Kawakami, A 2018, 'Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan', Arthritis Care and Research, vol. 70, no. 12, pp. 1719-1726. https://doi.org/10.1002/acr.23551
Nishino, Ayako ; Kawashiri, Shin ya ; Koga, Tomohiro ; Iwamoto, Naoki ; Ichinose, Kunihiro ; Tamai, Mami ; Nakamura, Hideki ; Origuchi, Tomoki ; Ueki, Yukitaka ; Yoshitama, Tamami ; Eiraku, Nobutaka ; Matsuoka, Naoki ; Okada, Akitomo ; Fujikawa, Keita ; Hamada, Hiroaki ; Tsuru, Tomomi ; Nagano, Shuji ; Arinobu, Yojiro ; Hidaka, Toshihiko ; Kawakami, Atsushi. / Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan. In: Arthritis Care and Research. 2018 ; Vol. 70, No. 12. pp. 1719-1726.
@article{6dd72e77738a4397ae3ef00e8298aec6,
title = "Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan",
abstract = "Objective: To explore the variables associated with initial favorable power Doppler (PD) ultrasound (US) response induced by biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA). Methods: We have been prospectively investigating the course of active RA patients using US after the introduction of b/tsDMARDs in the Kyushu region of Japan since June 2013. A total of 150 patients have completed the first 6 months of observation at present and have been evaluated. US was assessed in 22 joints of bilateral hands using gray-scale and PD images on a scale from 0–3. The sum of these scores was used as the indicator of US disease activity. We defined PD remission as attaining a total PD score of 0 at 6 months and investigated the associated variables by multivariate logistic regression analysis. Results: The total PD and gray-scale scores and the clinical composite measures significantly improved at 6 months, whereas these reductions were less in bDMARD switchers as compared with bDMARD-naive patients. Multivariate logistic regression analysis showed that short disease duration, the absence of any previous use of bDMARDs, and low total PD scores at baseline were independent predictors of PD remission at 6 months. Conclusion: This present prospective US cohort has for the first time shown the variables that are associated with initial PD response to b/tsDMARDs.",
author = "Ayako Nishino and Kawashiri, {Shin ya} and Tomohiro Koga and Naoki Iwamoto and Kunihiro Ichinose and Mami Tamai and Hideki Nakamura and Tomoki Origuchi and Yukitaka Ueki and Tamami Yoshitama and Nobutaka Eiraku and Naoki Matsuoka and Akitomo Okada and Keita Fujikawa and Hiroaki Hamada and Tomomi Tsuru and Shuji Nagano and Yojiro Arinobu and Toshihiko Hidaka and Atsushi Kawakami",
year = "2018",
month = "12",
day = "1",
doi = "10.1002/acr.23551",
language = "English",
volume = "70",
pages = "1719--1726",
journal = "Arthritis Care and Research",
issn = "2151-464X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan

AU - Nishino, Ayako

AU - Kawashiri, Shin ya

AU - Koga, Tomohiro

AU - Iwamoto, Naoki

AU - Ichinose, Kunihiro

AU - Tamai, Mami

AU - Nakamura, Hideki

AU - Origuchi, Tomoki

AU - Ueki, Yukitaka

AU - Yoshitama, Tamami

AU - Eiraku, Nobutaka

AU - Matsuoka, Naoki

AU - Okada, Akitomo

AU - Fujikawa, Keita

AU - Hamada, Hiroaki

AU - Tsuru, Tomomi

AU - Nagano, Shuji

AU - Arinobu, Yojiro

AU - Hidaka, Toshihiko

AU - Kawakami, Atsushi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Objective: To explore the variables associated with initial favorable power Doppler (PD) ultrasound (US) response induced by biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA). Methods: We have been prospectively investigating the course of active RA patients using US after the introduction of b/tsDMARDs in the Kyushu region of Japan since June 2013. A total of 150 patients have completed the first 6 months of observation at present and have been evaluated. US was assessed in 22 joints of bilateral hands using gray-scale and PD images on a scale from 0–3. The sum of these scores was used as the indicator of US disease activity. We defined PD remission as attaining a total PD score of 0 at 6 months and investigated the associated variables by multivariate logistic regression analysis. Results: The total PD and gray-scale scores and the clinical composite measures significantly improved at 6 months, whereas these reductions were less in bDMARD switchers as compared with bDMARD-naive patients. Multivariate logistic regression analysis showed that short disease duration, the absence of any previous use of bDMARDs, and low total PD scores at baseline were independent predictors of PD remission at 6 months. Conclusion: This present prospective US cohort has for the first time shown the variables that are associated with initial PD response to b/tsDMARDs.

AB - Objective: To explore the variables associated with initial favorable power Doppler (PD) ultrasound (US) response induced by biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA). Methods: We have been prospectively investigating the course of active RA patients using US after the introduction of b/tsDMARDs in the Kyushu region of Japan since June 2013. A total of 150 patients have completed the first 6 months of observation at present and have been evaluated. US was assessed in 22 joints of bilateral hands using gray-scale and PD images on a scale from 0–3. The sum of these scores was used as the indicator of US disease activity. We defined PD remission as attaining a total PD score of 0 at 6 months and investigated the associated variables by multivariate logistic regression analysis. Results: The total PD and gray-scale scores and the clinical composite measures significantly improved at 6 months, whereas these reductions were less in bDMARD switchers as compared with bDMARD-naive patients. Multivariate logistic regression analysis showed that short disease duration, the absence of any previous use of bDMARDs, and low total PD scores at baseline were independent predictors of PD remission at 6 months. Conclusion: This present prospective US cohort has for the first time shown the variables that are associated with initial PD response to b/tsDMARDs.

UR - http://www.scopus.com/inward/record.url?scp=85052090838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052090838&partnerID=8YFLogxK

U2 - 10.1002/acr.23551

DO - 10.1002/acr.23551

M3 - Article

C2 - 29481732

AN - SCOPUS:85052090838

VL - 70

SP - 1719

EP - 1726

JO - Arthritis Care and Research

JF - Arthritis Care and Research

SN - 2151-464X

IS - 12

ER -